Q2 2024 Earnings Forecast for Krystal Biotech, Inc. (NASDAQ:KRYS) Issued By William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at William Blair raised their Q2 2024 earnings estimates for Krystal Biotech in a note issued to investors on Tuesday, July 16th. William Blair analyst T. Lugo now expects that the company will post earnings of $0.67 per share for the quarter, up from their previous forecast of $0.49. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.06 per share. William Blair also issued estimates for Krystal Biotech’s FY2024 earnings at $2.57 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. The firm’s quarterly revenue was up 452400.0% on a year-over-year basis. During the same period last year, the business posted ($1.76) EPS.

A number of other equities analysts also recently commented on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a research note on Monday, May 6th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $177.63.

Krystal Biotech Trading Down 0.6 %

Shares of KRYS stock opened at $207.30 on Thursday. The firm has a fifty day moving average price of $174.92 and a 200 day moving average price of $156.88. The company has a market cap of $5.92 billion, a P/E ratio of 110.86 and a beta of 0.84. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $214.98.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC increased its stake in shares of Krystal Biotech by 112.5% during the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after acquiring an additional 383,495 shares during the period. Fiera Capital Corp acquired a new position in shares of Krystal Biotech during the fourth quarter worth about $1,973,000. Vanguard Group Inc. increased its stake in shares of Krystal Biotech by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock worth $302,182,000 after acquiring an additional 35,632 shares during the period. Janney Montgomery Scott LLC acquired a new position in shares of Krystal Biotech during the first quarter worth about $3,175,000. Finally, Braidwell LP increased its stake in shares of Krystal Biotech by 153.2% during the fourth quarter. Braidwell LP now owns 196,200 shares of the company’s stock worth $24,341,000 after acquiring an additional 118,703 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Krystal Biotech

In related news, Director Julian S. Gangolli sold 20,000 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Julian S. Gangolli sold 20,000 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).